A phase I trial of CC-486, lenalidomide, obinutuzumab in relapsed/refractory indolent non-Hodgkin lymphoma

被引：0
|
作者：
Othman, Tamer [1 ,2 ]
Marquez-Arreguin, Gabriel [1 ]
Esteghamat, Naseem [1 ]
Tuscano, Joseph [1 ,3 ]
机构：
[1] Univ Calif Davis, Sch Med, Dept Internal Med, Div Malignant Hematol Cellular Therapy & Transplan, Sacramento, CA USA
[2] Univ Calif San Francisco, Sch Med, Dept Internal Med, Div Hematol & Oncol, San Francisco, CA USA
[3] Northern Calif Hlth Care Syst, Vet Adm, Martinez, CA USA
来源：
LEUKEMIA & LYMPHOMA | 2024年
关键词：
REFRACTORY FOLLICULAR LYMPHOMA; SINGLE-ARM; MULTICENTER; METHYLATION;
D O I：
10.1080/10428194.2024.2443552
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] A Phase I Trial of CC-486, Lenalidomide, Obinutuzumab in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
    Marquez-Arreguin, Gabriel
    Othman, Tamer
    Esteghamat, Naseem S.
    Abedi, Mehrdad
    Socola, Francisco Andres
    Tuscano, Joseph M.
    BLOOD, 2024, 144 : 6317 - 6318
  • [2] Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas
    Gabellier, Ludovic
    Cartron, Guillaume
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (02) : 85 - 93
  • [3] Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
    Christian, Beth A.
    Huang, Ying
    Ayyappan, Sabarish
    Baiocchi, Robert A.
    Brammer, Jonathan E.
    Epperla, Narendranath
    Jaglowski, Samantha
    William, Basem M.
    Awan, Farrukh T.
    Maddocks, Kami J.
    Blum, Kristie A.
    BLOOD, 2019, 134
  • [4] Phase II trial for lenalidomide alone in relapsed/refractory aggressive non-Hodgkin lymphoma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (05): : 339 - 339
  • [5] Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma
    Barr, Paul M.
    Fu, Pingfu
    Lazarus, Hillard M.
    Horvath, Nancy
    Gerson, Stanton L.
    Koc, Omer N.
    Bahlis, Nizar J.
    Snell, Michael R.
    Dowlati, Afshin
    Cooper, Brenda W.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (01) : 89 - 96
  • [6] Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    Kallam, Avyakta
    Meza, Jane
    Bierman, Philip
    Lunning, Matthew A.
    Bociek, R. Gregory
    Armitage, James Olen
    Vose, Julie M.
    BLOOD, 2017, 130
  • [7] A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma
    Bond, David A.
    Huang, Ying
    Christian, Beth A.
    Jaglowski, Samantha
    Benson, Don
    Alinari, Lapo
    Baiocchi, Robert A.
    Cohen, Jonathon B.
    Blum, Kristie A.
    Maddocks, Kami J.
    LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1750 - 1753
  • [8] Phase I Trial of Bortezomib and Everolimus in Relapsed/Refractory Non-Hodgkin Lymphoma
    Hill, Brian T.
    Smith, Mitchell R.
    Mears, Jennifer
    Healy, Amy
    Shelley, Meredeth
    Wyckhouse, Jeanie
    Kakish, Janice
    Jagadeesh, Deepa
    Dean, Robert M.
    Pohlman, Brad
    Smith, Stephen D.
    BLOOD, 2014, 124 (21)
  • [9] A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma
    Fowler, Nathan H.
    Nastoupil, Loretta J.
    Chin, Collin
    Strati, Paolo
    Hagemeister, Fredrick B.
    Fayad, Luis E.
    Westin, Jason R.
    Forbes, Sheryl G.
    Arafat, Janine
    Feng, Lei
    Nair, Ranjit
    Steiner, Raphael E.
    Samaniego, Felipe
    Neelapu, Sattva S.
    BLOOD, 2019, 134
  • [10] Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
    Phillips, Tycel
    Chan, Henry
    Tam, Constantine S.
    Tedeschi, Alessandra
    Johnston, Patrick
    Oh, Sung Yong
    Opat, Stephen
    Eom, Hyeon-Seok
    Allewelt, Heather
    Stern, Jennifer C.
    Tan, Ziwen
    Novotny, William
    Huang, Jane
    Trotman, Judith
    BLOOD ADVANCES, 2022, 6 (11) : 3472 - 3479
12345